[Safety and immunogenicity of lyophilized live attenuated domestic varicella vaccine]
- PMID: 20084971
[Safety and immunogenicity of lyophilized live attenuated domestic varicella vaccine]
Abstract
Objective: To evaluate the safety and immunogenicity of the lyophilized live attenuated domestic varicella vaccine of Oka strain in Zhejiang province.
Methods: 785 susceptible children aged 1-13 years, who had no history of VZV infection and had not been immunized, were observed. RESULTS The results showed that 2.29% children had adverse reactions after 30 mins of inoculation, 3.69% children had adverse reactions after 4 hours, 3.82% children had adverse reactions after 24 hours, 1.78% children had adverse reactions after 48 hours, 0.25% children had adverse reactions after 72 hours, no adverse reactions were observed after six weeks. There were 3.82% children had fever, The incidence rate of other adverse reactions such as swell and scleroma were low. The vaccine had high sero-converson rate.
Conclusion: The results showed that it has good safety and immunogenicity of the live attenuated domestic varicella vaccine.
Similar articles
-
Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: a randomized controlled study.Hum Vaccin Immunother. 2015;11(2):443-9. doi: 10.1080/21645515.2014.1004031. Hum Vaccin Immunother. 2015. PMID: 25692656 Free PMC article. Clinical Trial.
-
Long-term clinical studies of varicella vaccine at a regional hospital in Japan and proposal for a varicella vaccination program.Vaccine. 2013 Dec 9;31(51):6155-60. doi: 10.1016/j.vaccine.2013.10.060. Epub 2013 Oct 30. Vaccine. 2013. PMID: 24183712 Review.
-
Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial.Clin Microbiol Infect. 2019 Aug;25(8):1026-1031. doi: 10.1016/j.cmi.2018.12.033. Epub 2019 Jan 4. Clin Microbiol Infect. 2019. PMID: 30616012 Clinical Trial.
-
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.Lancet Infect Dis. 2024 Aug;24(8):922-934. doi: 10.1016/S1473-3099(24)00159-2. Epub 2024 Apr 10. Lancet Infect Dis. 2024. PMID: 38614117 Clinical Trial.
-
The safety profile of varicella vaccine: a 10-year review.J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. J Infect Dis. 2008. PMID: 18419392 Review.
Cited by
-
Immunogenicity and safety of the domestic and imported live-attenuated varicella vaccine in healthy Chinese populations: a systematic review and meta-analysis.BMC Infect Dis. 2025 Jul 5;25(1):897. doi: 10.1186/s12879-025-11275-w. BMC Infect Dis. 2025. PMID: 40618017 Free PMC article.
-
Comparison of the Whole-Genome Sequence of an Oka Varicella Vaccine from China with Other Oka Vaccine Strains Reveals Sites Putatively Critical for Vaccine Efficacy.J Virol. 2019 Apr 17;93(9):e02281-18. doi: 10.1128/JVI.02281-18. Print 2019 May 1. J Virol. 2019. PMID: 30728261 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical